LIFR Antibodies

Leukemia inhibitory factor receptor (LIFR)

Signal-transducing molecule. May have a common pathway with IL6ST.

The soluble form inhibits the biological action of LIF by blocking its binding to receptors on target cells. .

Gene Information

Human
Gene Name:	LIFR
Uniprot:	P42702
Entrez:	3977

Family

Belongs to:
type I cytokine receptor family

Alternative Names

CD118 antigen; CD118; FLJ98106; FLJ99923; leukemia inhibitory factor receptor alpha; leukemia inhibitory factor receptor; LIF R alpha; LIF R beta; LIF receptor; LIFR alpha; LIFR; LIF-R; LIFRa; SJS2; STWS; SWS

Molecular Weight

Mass (kDA):
123.743 kDA

Genomic Context

Human
Location:	5p13.1
Sequence:	5; NC_000005.10 (38474668..38606290, complement)

Subcellular Localizations

[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.

Diseases

• Leukemia
• Neoplasms
• Inflammation
• Nervousness
• Malignant Neoplasms
• Janiceps
• Endometrial Polyp
• Carcinoma
• Liver Carcinoma
• Hypertrophy
• Neuroblastoma
• Pituitary Diseases
• Myeloid Leukemia

• Multiple Myeloma
• Malignant Paraganglionic Neoplasm
• Choriocarcinoma
• Infertility
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Chimera Disorder

Interacting Proteins

• CNTF

Pathways

• Secretion
• Cell Growth
• Cell Proliferation
• Regeneration
• Cell Differentiation
• Cell Death
• Embryo Development
• Localization
• Pathogenesis
• Embryo Implantation
• Neurogenesis
• Inflammatory Response
• Reverse Transcription

• Bone Resorption
• Cell Cycle
• Macrophage Differentiation
• Osteoblast Differentiation
• System Development
• Decidualization
• Cell Adhesion

PTMs

• Phosphorylation
• Methylation
• Glycosylation
• Cleavage

• Acetylation
• Iodination
• Demethylation
• Oxidation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/LIFR

The Best Uses Of The LIFR Marker In Boster Bio

The IL6 cell cytokine, essential for boster bio, is the most crucial. It is crucial for healthy functioning of the immune systems. The LIFR marker is a measure of this cytokine, which is a key component of the immune system. If you are interested in learning more about the LIFR marker, call Sanbio today. They're ready to help with any questions you have regarding boster bio or custom services, and BeNeLux delivery.

Cytokine IL6

The IL6 cytokine is derived from the receptor on the cell surface that is able to bind to IL-6. The cytokine then triggers itself by binding to its nonsignaling receptor (also known as CD126). This process results in the activation of receptor-associated-kinases (RAKs) and the regulation of STAT1 and STAT3 activity. IL-6R is expressed by various Hepatocytes and inflammatory cells. It is also available in liquid form.

Research on the IL-6 cell-surface cytokine is likely to improve the diagnosis, treatment, and prognosis for cancer. Monoclonal antibodies that target IL-6 might be a valuable tool in the development of new cancer therapies. Further, research on new regulators of cytokines belonging to the IL-6 family could lead to the creation of new monoclonal antibodies. In addition, the IL-6 family cytokines could be used in combination treatments to fight cancer.

Screening patients suffering from RA by cytokine IL-6 is a useful tool to determine whether the RA drug is inhibiting the IL-6 receptor. Clinical trials on the LIFR marker have also shown it useful for predicting the reaction to a specific drug. In the initial phase of the study, 18 patients with active Castleman disease were enrolled. To assess the efficacy of the treatment, biochemical markers and general fatigue measures were utilized.

Recent evidence has shown that IL-6 may be involved in lung tumorigenesis. Its presence was associated with increased invasive adenocarcinoma and adenomatous hyperplasia in transgenic mice. Furthermore, IL-6 has also been linked to the growth of lung cancer in KRAS-driven mice. Hence, using the LIFR marker to detect the presence of IL-6 in the body of a patient is a useful diagnostic tool for lung cancer.

The IL-6 cytokine is an excellent predictor of death in patients suffering from COVID-19. Moreover, it correlates well with clinical signs and radiologic changes. The IL-6 kinetics of this study were calculated using the day following symptomatology. The group of patients who survived experienced the highest levels of IL-6 on day 4, while non-survivors also experienced a similar peak around the 10th day after onset of symptoms. As patients recovered, IL-6 levels decreased.

At-risk males have higher levels of IL-6 compared to normal subjects. After the adjustment for C-reactive proteins at baseline the results were statistically significant. The higher levels of IL-6 were associated with a 44% greater risk of future myocardial infarction. These findings suggest that IL-6 Cytokine could be used to detect underlying cardiac disease.

Plasma samples had higher levels of IL-6 than serum. These results suggest that sample handling mistakes could boost IL-6 cytokine levels. The IL-6-producing cytokine is the best LIFR marker for detecting immune-related diseases. It is crucial to keep in mind that samples are affected by factors that affect the analysis. The temperatures at which the samples were kept varied between the groups.

The cytokine IL-6 is involved in a wide range of biological activities, including the regulation of the immune response, acute-phase reaction, hematopoiesis and bone metabolism. It is mediated through an innate immune response receptor system that is composed of two membrane proteins that are IL-6R and gp130. They create a functional high-affinity receiver complex.

The differences in these markers allow for an improved prognostication in patients with postoperative sepsis. However the authors of the prospective study could not find any significant differences between PCT, IL-6, or CRP. Additionally, additional surgical trauma might have had an effect on the inflammatory markers. In our study, 13.4% of patients required surgical eradication.

Adipocytes release IL-6, which is an inflammatory cytokine. The biochemical plausibility and importance of IL-6 is a strong. It is a vital cell signalling system in pathways associated with asthma. However this cytokine was mostly ignored due to the absence of evidence. This study raises more questions than it answers.

Serum levels of IL-6 for patients with RA and Castleman disease were comparable at baseline but significantly higher than those in patients who were not affected by the condition. Researchers discovered that IL-6 levels in serum were significantly higher in Castleman disease patients than those with RA between days 14 and 42. Despite the relatively modest differences in the results, they were significant. This could be due to the fact that the RA group suffers more severe symptoms and the serum levels of IL-6 are higher.

The IL6 Cytokine comes from a gene known as mxA. This gene regulates inflammation processes. The cytokine also plays a role in the immune response. It is not a reliable biomarker but it can help determine the cause of the illness. If the cytokine can be detected at the beginning of the illness, it is likely that it can be used to determine what is causing the illness.